Researchers at Zhejiang University have developed S²ALM, a Sequence-Structure multi-level pre-trained Antibody Language Model, an advanced AI framework to innovate antibody engineering. This model integrates sequence and structural information, enabling improved therapeutic antibody design with higher accuracy and efficiency. This advancement promises to accelerate drug discovery pipelines, especially in developing antibodies targeted at COVID-19 and other diseases, addressing challenges in therapeutic development amid ongoing global health concerns.